Scarica l'app Stockscreener
0.20
11.31%
-0.0255
Quince Therapeutics Inc Borsa (QNCX) Ultime notizie
Quince Therapeutics Pursues Reverse Merger Amid Restructuring Effort - The Globe and Mail
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours - Benzinga
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Quince Therapeutics engages LifeSci Capital for strategic alternatives - marketscreener.com
Quince Therapeutics Inc (QNCX) Stock Price, Quote, News & History - Benzinga
Quince Therapeutics stock plummets after revealing strategic alternatives - Investing.com
Quince TherapeuticsOn Feb 9, Engaged Lifesci Capital For Strategic AlternativesSEC Filing - TradingView
Best Penny Stocks To Watch Now – February 10th - Defense World
Small Cap Stocks To Follow Now – February 10th - Defense World
Does Quince Therapeutics Inc. align with a passive investing strategyTrade Entry Summary & Free Weekly Watchlist of Top Performers - mfd.ru
Quince Therapeutics Stock Extends Rally On Strategic Review - Benzinga
Quince Therapeutics (QNCX) Stock Surges 300% on Strategic Alternative Plans - parameter.io
Is Quince Therapeutics Inc. a play on infrastructure spendingMarket Trend Report & Accurate Buy Signal Notifications - mfd.ru
Quince Therapeutics (QNCX) Stock Erupts 300% as Buyout Rumors Emerge - Blockonomi
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
QNCX Stock Price and Chart — NASDAQ:QNCX - TradingView
Quince Therapeutics (QNCX) Stock: What’s Behind the 300% Rally? - CoinCentral
Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive - TechStock²
Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
Why is Quince Therapeutics stock soaring Tuesday? - MSN
QNCX (Quince Therapeutics) NASDAQ intraday up 182.82% to $0.39: watch strategic-review momentum - Meyka
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Mena FN
Why Is Quince Therapeutics Stock Soaring Tuesday? - Benzinga
Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move - TechStock²
Quince Therapeutics Exploring Strategic Alternatives; Stock Soars - Nasdaq
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - PharmiWeb.com
Quince Therapeutics stock soars after engaging LifeSci Capital as advisor By Investing.com - Investing.com Australia
Quince Therapeutics stock soars after engaging LifeSci Capital as advisor - Investing.com
Fed Meeting: What is Quince Therapeutics Incs debt to equity ratio2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn
Quince Therapeutics Announces Significant Board of Directors Resignations - The Globe and Mail
Quince stock plunges 95% following failed clinical trial for inherited childhood disease - The Business Journals
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure - Clinical Trials Arena
Why did QNCX stock plummet over 90% today? - MSN
Lucid Cap Mkts Downgrades Quince Therapeutics (NASDAQ:QNCX) to Strong Sell - Defense World
Quince Therapeutics (NASDAQ:QNCX) Cut to Hold at Brookline Capital Management - Defense World
Quince’s eDSP on ice after Neat phase III fails in A-T - bioworld.com
Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground - Citeline News & Insights
This Codere Online Luxembourg Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga
QNCX Downgraded to 'Hold' by D. Boral Capital Analyst | QNCX Sto - GuruFocus
Quince Therapeutics (QNCX) Downgraded by Citizens to Market Perf - GuruFocus
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital By Investing.com - Investing.com Nigeria
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital - Investing.com Nigeria
Lucid Capital Markets downgrades Quince Therapeutics stock to Sell after failed trial By Investing.com - Investing.com India
Lucid Capital Markets downgrades Quince Therapeutics stock to Sell after failed trial - Investing.com
Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp - MarketBeat
Quince Therapeutics (QNCX) Downgraded Following Phase 3 Trial Mi - GuruFocus
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Quince Therapeutics stock rating downgraded by Citizens after Phase 3 trial failure - Investing.com Nigeria
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):